UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 299,301 shares of the biotechnology company's stock after buying an additional 31,098 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.31% of Sarepta Therapeutics worth $36,392,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Park Avenue Securities LLC acquired a new position in Sarepta Therapeutics during the 4th quarter worth approximately $205,000. Nisa Investment Advisors LLC grew its holdings in Sarepta Therapeutics by 23.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,317 shares of the biotechnology company's stock worth $160,000 after acquiring an additional 247 shares during the last quarter. Fifth Third Bancorp increased its holdings in Sarepta Therapeutics by 219.7% in the fourth quarter. Fifth Third Bancorp now owns 1,832 shares of the biotechnology company's stock valued at $223,000 after purchasing an additional 1,259 shares during the period. PFG Investments LLC raised its position in shares of Sarepta Therapeutics by 1.2% during the fourth quarter. PFG Investments LLC now owns 26,998 shares of the biotechnology company's stock worth $3,283,000 after acquiring an additional 324 shares during the last quarter. Finally, Blue Trust Inc. raised its holdings in Sarepta Therapeutics by 56.9% during the 4th quarter. Blue Trust Inc. now owns 891 shares of the biotechnology company's stock worth $111,000 after purchasing an additional 323 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Wall Street Analysts Forecast Growth

SRPT has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft dropped their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Morgan Stanley reduced their price objective on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Guggenheim dropped their target price on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Royal Bank of Canada reduced their price target on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a report on Wednesday, May 7th. Finally, Oppenheimer dropped their price objective on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $122.61.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT traded down $1.12 on Wednesday, reaching $37.23. 3,271,164 shares of the company's stock were exchanged, compared to its average volume of 1,798,386. The firm has a market cap of $3.66 billion, a price-to-earnings ratio of 29.78 and a beta of 0.85. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a fifty day simple moving average of $53.05 and a 200-day simple moving average of $93.24. Sarepta Therapeutics, Inc. has a 52 week low of $34.10 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company's revenue was up 80.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.73 EPS. As a group, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.70% of the stock is owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.